Sella T, et al. - In a retrospectively identified population of women diagnosed with nonmetastatic breast cancer and started on hormonal therapy (HT) between January 2000 and December 2007, researchers analyzed rates of adherence and persistence of adjuvant HT. The participants were 4,178 and tamoxifen was the initial HT in nearly 95% of patients. A total of 955 (23%) patients early discontinued therapy during 5 years follow-up. The mean proportion of days covered was 82.9%. An increased risk of early discontinuation and nonadherence was reported in relation to younger age and low BMI. Among Israeli breast cancer survivors examined in this study, the observed adherence and persistence with HT were comparable to those in international reports. Findings call for interventions to detect and prevent suboptimal HT adherence.